SL-325 Phase 1 shows 3.7% ADA, durable DR3 blockade; 96% of warrants exercised for ~$49.3M additional proceeds.

Shattuck Labs, Inc.

Phase 1: ADA detected in only 3.7% (2/54) of SL-325 recipients; low titer (≤16) with no PK/RO impact.
Complete DR3 occupancy at all doses ≥0.1 mg/kg; PK modeling suggests >3 months blockade at doses ≥1 mg/kg.
No serious TEAEs; all TRAEs Grade 1; no DR3 agonism or lymphocyte proliferation observed.
RECEPTIVE-CD1 Phase 2b in Crohn's expected to start Q3 2026; primary endpoint endoscopic response at Week 12.
Warrant exercise for ~50.6M shares (96% of Aug 2025 placement) yields ~$54.9M gross; cash runway into 2029.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.